“…Because most of the drugs (eg, asthma drugs) are not soluble in CO 2 , SAS processes provide an easy and excellent way to produce dry powder inhalation formulations. 163,164 SFEE can provide uniform crystalline drug nanoparticles, composite nanoparticles containing polymeric materials and the drugs, and nanosuspensions. 165,166 For instance, Chattopadhyay and colleagues 23 used a continuous SFEE method to produce nanoparticle suspensions containing one of three lipids (tripalmitin, tristearin, or gelucire 50/13), and one of two model drugs (indomethacin or ketoprofen).…”